Physician profile
Dunya Mohammad
NPI 1053796409
$482.88
in general payments reported to CMS, 2019-2025
11 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Pediatric Nephrology provider received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.97 · 2022: $15.62 · 2023: $66.13 · 2024: $104 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $447 · Education: $1.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.19 |
| Education | $1.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $119.75 | 2023-2025 | Givlaari, Oxlumo |
| Dexcom, INC. | $115.55 | 2023-2025 | Dexcom G6 Transmitter |
| Calliditas Therapeutics US INC. | $52.28 | 2025 | Tarpeyo |
| Novo Nordisk INC | $50.23 | 2025 | Sogroya |
| Sanofi-Aventis U.S. LLC | $36.91 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $29.41 | 2025 | Katerzia |
| Neurocrine Biosciences, INC. | $27.20 | 2025 | |
| Medtronic, INC. | $18.97 | 2021 | |
| Tandem Diabetes Care, INC. | $15.86 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $15.62 | 2022 | |
| Travere Therapeutics, INC. | $1.10 | 2025 | Thiola |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dunya Mohammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.